MRK supply chain intelligence for Merck & Co., Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Merck & Co., Inc. (MRK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 92% | Reciprocal relationship from BMY graph: Reciprocal relationship from MRK graph: Reblozyl is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a glo… |
| BMY | Bristol-Myers Squibb Company | 92% | Reblozyl is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb Company (BMS) |
| HBIO | Harvard Bioscience, Inc. | 92% | Reciprocal relationship from HBIO graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HBIO graph: Our pharmaceutical and biotechnology customers include companies and research… |
| INTS | Intensity Therapeutics, Inc. | 92% | Reciprocal relationship from INTS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from INTS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from INTS gra… |
| CIDARA | CIDARA | 90% | Merck acquired Cidara, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $ 9.2 billion |
| DAIICHI-SANKYO | DAIICHI-SANKYO | 90% | Merck is working with Daiichi Sankyo to address FDA feedback |
| J-J-INNOVATIVE-MEDICINE | J-J-INNOVATIVE-MEDICINE | 90% | Under a previous license agreement between Cidara and J&J Innovative Medicine...J&J Innovative Medicine is eligible to receive up to $ 105 million in regulatory milestones and up to $ 455 million in … |
| NEUP | Neuphoria Therapeutics Inc. | 85% | Reciprocal relationship from NEUP graph: the Carina Biotech License, and $67.9 million from Australian research and development credits and government grants and assistance. |
| PSNL | Personalis, Inc. | 85% | Reciprocal relationship from PSNL graph: Reciprocal relationship from MRK graph: Reciprocal relationship from PSNL graph: he sale of its equity securities and cash from operations. million was reclas… |
| THIRD-PARTY | THIRD-PARTY | 85% | The Company is working to reduce its Scope 3 emissions through a robust supplier engagement approach to drive collaboration upstream and downstream in its value chain |
| VERONA-PHARMA | VERONA-PHARMA | 85% | Animal health sales growth was due to the performance of both livestock and companion animal products. (which was obtained as part of the October 2025 acquisition of Verona Pharma plc [Verona Pharma]). |
| ADAG | Adagene Inc. | 72% | Reciprocal relationship from ADAG graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ADAG graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ADAG gra… |
| ARE | Alexandria Real Estate Equities, Inc. | 72% | Reciprocal relationship from ARE graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ARE graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ARE graph:… |
| AVIR | Atea Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AVIR graph: Reciprocal relationship from MRK graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from MRK graph: Reciprocal relationship from AVIR gra… |
| BLRX | BioLineRx Ltd. | 72% | Reciprocal relationship from BLRX graph: quent autologous transplantation in patients with multiple myeloma. Following this approval, we commenced commercialization of motixafortide in the U.S. indep… |
| BNBX | BNB Plus Corp. | 72% | Reciprocal relationship from BNBX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BNBX graph: ices for the fiscal year ended September 30, 2024 includes 26% and 17% from t… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CAH graph:… |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 72% | Reciprocal relationship from CBIH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CBIH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CBIH gra… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CHRS gra… |
| CPMV | Mosaic ImmunoEngineering, Inc. | 72% | Reciprocal relationship from CPMV graph: ate our business without infringing on third-party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third part… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: h activities and efforts to establish and run clinical trials for Varseta-M a… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with… |
| DKS | DICK'S Sporting Goods, Inc. | 72% | Reciprocal relationship from DKS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from DKS graph: ent, design, data, analytics, engineering and foundational technology. Prior to… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: pagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| ELAN | Elanco Animal Health Incorporated | 72% | Reciprocal relationship from ELAN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ELAN graph: utical production processes are complex, highly regulated and can vary widely… |
| ENLV | Enlivex Ltd. | 72% | Reciprocal relationship from ENLV graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ENLV graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ENLV gra… |
| ENZN | Viskase Companies, Inc. | 72% | Reciprocal relationship from ENZN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ENZN graph: llion and $ 46.5 million, respectively. Revenue Recognition Royalty revenues … |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVAX gra… |
| EVFM | Evofem Biosciences, Inc. | 72% | Reciprocal relationship from EVFM graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain ou… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BAYER-AG | BAYER-AG | 92% | Alliance revenue from the collaboration grew 3% in the first quarter of 2026 primarily reflecting higher demand in Bayer’s marketing territories. |
| JANX | Janux Therapeutics, Inc. | 90% | Reciprocal relationship from JANX graph: Merck has the unilateral right to terminate the agreement in its entirety or on a Collaboration Target by Collaboration Target basis at any time and for any r… |
| OGN | Organon & Co. | 90% | Reciprocal relationship from OGN graph: Oss, Netherlands Women’s health Pandaan, Indonesia Cardiovascular, respiratory and dermatology Xochimilco, Mexico Cardiovascular and respiratory Most of our in… |
| THIRD-PARTY | THIRD-PARTY | 90% | Merck paid an additional 7% royalty on worldwide sales of Gardasil/Gardasil 9 to another third party |
| OGN | Organon & Co. | 85% | n ADC and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on f… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from MRK graph: he U.S. for first-line triple-negative-breast cancer (TroFuse-011 trial), Blackstone will be eligible to receive low-to… |
| AZN | AstraZeneca PLC | 72% | he U.S. for first-line triple-negative-breast cancer (TroFuse-011 trial), Blackstone will be eligible to receive low-to-mid single-digit royalties on net sales of sac-TMT subsequent to such approval … |
| BLRX | BioLineRx Ltd. | 72% | Reciprocal relationship from BLRX graph: quent autologous transplantation in patients with multiple myeloma. Following this approval, we commenced commercialization of motixafortide in the U.S. indep… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BMY graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BMY graph:… |
| BMY | Bristol-Myers Squibb Company | 72% | es will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights, and Merck will receive a % sales-based royalty. Merck will record its share… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BMYMP … |
| BMYMP | Bristol-Myers Squibb Co | 72% | es will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights, and Merck will receive a % sales-based royalty. Merck will record its share… |
| BNBX | BNB Plus Corp. | 72% | Reciprocal relationship from BNBX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from BNBX gra… |
| CAH | Cardinal Health, Inc. | 72% | . Includes cumulative translation adjustments. Amount in 2025 includes the reversal of $ million for a Zerbaxa (ceftolozane and tazobactam) sales-based milestone as it was determined that payment was… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CAH graph:… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs… |
| CORT | Corcept Therapeutics Incorporated | 72% | Reciprocal relationship from CORT graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CORT graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CORT gra… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX gra… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cG… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from DYN graph:… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| ELAN | Elanco Animal Health Incorporated | 72% | net sales of MK-1045, if approved. In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco aqua business) for total consideration of $ 1.3 billion. The Elanco aqua… |
| ELAN | Elanco Animal Health Incorporated | 72% | Reciprocal relationship from ELAN graph: utical production processes are complex, highly regulated and can vary widely from product to product. Shifting or adding manufacturing capacity can be a leng… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: The Chief Operating Officer joined the Company on March 14, 2022 and the Chief Financial Officer is expected to join the Company in August 2022. Russia’s Inva… |
| EVFM | Evofem Biosciences, Inc. | 72% | Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely dev… |
| EXOZ | eXoZymes, Inc. | 72% | Reciprocal relationship from EXOZ graph: ● predictable, single-product precision without undesired by-products. The technology delivers >99% food/pharma-grade purity, simplifying formulation and regu… |
| GLSI | Greenwich LifeSciences, Inc. | 72% | Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may o… |
| GLTO | Damora Therapeutics, Inc. | 72% | Reciprocal relationship from GLTO graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GLTO graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GLTO gra… |
| HOWL | Werewolf Therapeutics, Inc. | 72% | Reciprocal relationship from HOWL graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when… |
| HRTX | Heron Therapeutics, Inc. | 72% | Reciprocal relationship from HRTX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MRK-DEBT | Debt stack $53.9B | 90% | Market cache reports total debt of $53.9B. |
| MRK-DEBT-6901 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2010-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MRK-OWNER-MERCK-CO-INC | Merck & Co., Inc. | 90% | 13F overlay lists Merck & Co., Inc. as top holder; 1 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 1 | ['customer', 'supplier'] |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 1 | ['customer', 'supplier'] |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| EXOZ | eXoZymes, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BNBX | BNB Plus Corp. | 100.00 | 1 | ['customer', 'supplier'] |
| DKS | DICK'S Sporting Goods, Inc. | 100.00 | 1 | ['supplier'] |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 |